Serum albumin levels on admission are associated with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction

Angiology. 2015 Mar;66(3):278-85. doi: 10.1177/0003319714526035. Epub 2014 Mar 19.

Abstract

Low serum albumin (SA) levels are associated with increased cardiovascular mortality. We investigated whether baseline SA levels are associated with no-reflow following primary percutaneous coronary intervention (pPCI). A total of 536 patients (aged 60 ± 13 years; 74% men) who underwent pPCI were enrolled. The patients were divided into 2 groups: no-reflow and normal-reflow. No-reflow was defined as thrombolysis in myocardial infarction ≤2 flow. Admission SA levels were significantly lower in the no-reflow group than in the normal-reflow group (3.55 ± 0.44 vs 4.01 ± 0.32 mg/dL, P < .001). Also, high-sensitivity C-reactive protein (hsCRP), creatinine, creatine kinase myocardial band isoenzyme, and troponin T were significantly higher while hemoglobin and left ventricular ejection fraction (LVEF) were significantly lower in the no-reflow group. In multivariate analysis, SA level remained an independent predictor of angiographic no-reflow (odds ratio 0.114, 95% confidence interval 0.032-0.405, P = .001) together with LVEF, hsCRP, and baseline culprit artery patency. Admission SA level was an independent predictor of no-reflow after pPCI.

Keywords: acute myocardial infarction; no-reflow phenomenon; primary percutaneous coronary intervention; serum albumin level.

MeSH terms

  • Aged
  • Biomarkers / blood
  • C-Reactive Protein / analysis
  • Chi-Square Distribution
  • Coronary Angiography*
  • Female
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Myocardial Infarction / blood
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / therapy*
  • No-Reflow Phenomenon / blood
  • No-Reflow Phenomenon / diagnostic imaging
  • No-Reflow Phenomenon / etiology*
  • No-Reflow Phenomenon / physiopathology
  • Odds Ratio
  • Patient Admission*
  • Percutaneous Coronary Intervention / adverse effects*
  • Predictive Value of Tests
  • Risk Factors
  • Serum Albumin / analysis*
  • Serum Albumin, Human
  • Stroke Volume
  • Treatment Outcome
  • Vascular Patency
  • Ventricular Function, Left

Substances

  • ALB protein, human
  • Biomarkers
  • Serum Albumin
  • C-Reactive Protein
  • Serum Albumin, Human